The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
Plasmacytoid and conventional dendritic cells cooperate in crosspriming AAV capsid-specific CD8+ T cells
Open accessAbstract
Key Points: Crosspriming of AAV capsid-specific CD8+ T cells requires cooperation between distinct subsets of DCs. Innate immune sensing of the viral DNA genome induces cross-presentation of viral capsid in trans.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Despite evidence for various innate responses to AAV, the existence of other pathways leading to antigen-specific T cell responses has been unknown.24,25,43,44,45”
From TLR9-independent CD8+ T cell responses in hepatic AAV gene transfer through IL-1R1-MyD88 signaling (2024) · cites this paper as [25]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“all of the AAV-induced cytokines and chemokines can be upregulated by activation of TLR9 in the periphery using synthetic CpG-rich oligonucleotides.8,9,10,11,12,52,53,54,55,56,57,58”
From An innate immune response to adeno-associated virus genomes decreases cortical dendritic complexity and disrupts synaptic transmission (2024) · cites this paper as [11]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“the genome of the vector activates Toll-like receptor 9 (TLR9), a pattern recognition receptor that senses foreign DNA”
From Engineering adeno-associated viral vectors to evade innate immune and inflammatory responses (2021) · cites this paper as [18]
The cited source says what the claim attributes to it.
In the citing paper
“Plasmacytoid dendritic cells (pDCs) are critical for mounting a TLR9/MyD88-dependent early innate immune response to AAV vectors (15) and they subsequently orchestrate anti-capsid CD8+ T cell responses in vivo by activating conventional DCs to cross-present capsid antigen (18).”
From Engineering adeno-associated viral vectors to evade innate immune and inflammatory responses (2021) · cites this paper as [18]
In the citing paper
“Furthermore, the TLR9/MyD88 pathway is not only vital for mounting a CD8+ T-cell response against the AAV capsid but also liver and muscle-directed transgenes [28, 34, 35, 41].”
From Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer (2023) · cites this paper as [28]
In the citing paper
“Adaptive anti-capsid humoral [27] and cytotoxic [28, 29] immune responses have been shown to be restricted in vivo by inhibiting innate immune activation pathways.”
From Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer (2023) · cites this paper as [28]
In the citing paper
“Studies suggest that cooperation between plasmacytoid DCs, conventional DCs, and CD4+ T cells results in cross-presentation of AAV particles on MHC I, and, subsequently, activation of CD8+ T cells [28, 29].”
From Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer (2023) · cites this paper as [28]
In the citing paper
“Capsid-specific CD8+ T cells expand and potentially clear AAV transduced cells, which results in loss of transgene expression and inflammation of target organs [59, 60].”
From Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer (2023) · cites this paper as [60]
In the citing paper
“but did not participate directly in CD8+ T cell priming (42).”
From Pre-existing humoral immunity and complement pathway contribute to immunogenicity of adeno-associated virus (AAV) vector in human blood (2022) · cites this paper as [42]
In the citing paper
“In mice, cDCs were shown to play a role in priming of a cytotoxic T cell response against immunogenic ovalbumin peptide inserted into the AAV2 capsid protein sequence (42).”
From Pre-existing humoral immunity and complement pathway contribute to immunogenicity of adeno-associated virus (AAV) vector in human blood (2022) · cites this paper as [42]
In the citing paper
“More recent work has highlighted the role of innate immune system in response to AAV therapeutics (42–46)”
From Pre-existing humoral immunity and complement pathway contribute to immunogenicity of adeno-associated virus (AAV) vector in human blood (2022) · cites this paper as [42]
In the citing paper
“Indeed, both TLR9 and T1 IFNs (and also CD4+ T help) are requisite for anti-capsid CD8+ T cell priming (9, 15).”
From Effect of CpG Depletion of Vector Genome on CD8+ T Cell Responses in AAV Gene Therapy (2021) · cites this paper as [9]
In the citing paper
“Importantly, TLR9 sensing of AAV vector genomes has been shown to be required for anti-capsid CD8+ T cell responses (9–14).”
From Effect of CpG Depletion of Vector Genome on CD8+ T Cell Responses in AAV Gene Therapy (2021) · cites this paper as [9]
In the citing paper
“T1 IFN along with CD4+ T cell help contributes to licensing of cDCs, which then prime capsid specific CD8+ T cells (9, 15).”
From Effect of CpG Depletion of Vector Genome on CD8+ T Cell Responses in AAV Gene Therapy (2021) · cites this paper as [9]
In the citing paper
“Another limitation is that CpG depletion does not eliminate antibody formation against the capsid or transgene product, which can be modified by but does not depend on the TLR9-MyD88 pathway (9, 12, 15).”
From Effect of CpG Depletion of Vector Genome on CD8+ T Cell Responses in AAV Gene Therapy (2021) · cites this paper as [9]
In the citing paper
“However, it should be pointed out that even TLR9 deficient mice do not show complete abolishment of CD8+ T cell responses, as our current and published studies have shown (7–9).”
From Effect of CpG Depletion of Vector Genome on CD8+ T Cell Responses in AAV Gene Therapy (2021) · cites this paper as [9]
In the citing paper
“However, adaptive immune responses to the capsid were found to be independent of TLR2 in a murine model of muscle gene transfer.”
From Innate immune sensing of adeno-associated virus vectors (2024) · cites this paper as [26]
In the citing paper
“Thus far, a strong dependency of immune responses to AAV gene transfer on TLR2 has not been documented.”
From Innate immune sensing of adeno-associated virus vectors (2024) · cites this paper as [26]
In the citing paper
“Several other studies showed no effect of STING deficiency on B or T cell responses.”
From Innate immune sensing of adeno-associated virus vectors (2024) · cites this paper as [26]
In the citing paper
“Sensing of the AAV genome by TLR9 in plasmacytoid dendritic cells (pDCs) conditions conventional cross-presenting dendritic cells (cDCs) via IFN-I to prime AAV capsid-specific CD8+ T cells.17,24,25,26”
From TLR9-independent CD8+ T cell responses in hepatic AAV gene transfer through IL-1R1-MyD88 signaling (2024) · cites this paper as [25]
In the citing paper
“In this regard, the requirements are similar to those for MHC class I presentation of AAV capsid antigen.25,41”
From TLR9-independent CD8+ T cell responses in hepatic AAV gene transfer through IL-1R1-MyD88 signaling (2024) · cites this paper as [25]
In the citing paper
“In lymphoid organs, anti-viral responses may be orchestrated by migration of pDCs and XCR1+ DCs to sites of virally infected APCs, where they co-cluster, allowing pDCs to condition XCR1+ DCs through IFN-I.25,26”
From TLR9-independent CD8+ T cell responses in hepatic AAV gene transfer through IL-1R1-MyD88 signaling (2024) · cites this paper as [25]
In the citing paper
“CD8+ T cell responses against input capsid may develop faster in mice than against the transgene product.25,65”
From TLR9-independent CD8+ T cell responses in hepatic AAV gene transfer through IL-1R1-MyD88 signaling (2024) · cites this paper as [25]
In the citing paper
“XCR1+ cDCs closely cooperate with pDCs in cross-priming of CD8+ T cells, with pDCs conditioning the XCR1+ cDCs with cytokines.25,26,35”
From TLR9-independent CD8+ T cell responses in hepatic AAV gene transfer through IL-1R1-MyD88 signaling (2024) · cites this paper as [25]
In the citing paper
“However, this does not apply here because AAV8 does not elicit a CD8+ T cell response against capsid in mice and because the vector dose was anyhow too low to generate such a response.25,66,67”
From TLR9-independent CD8+ T cell responses in hepatic AAV gene transfer through IL-1R1-MyD88 signaling (2024) · cites this paper as [25]
In the citing paper
“Cross-priming of anti-viral CD8+ T cell responses following TLR9 activation in pDCs requires IFNAR expression in cDCs.25”
From TLR9-independent CD8+ T cell responses in hepatic AAV gene transfer through IL-1R1-MyD88 signaling (2024) · cites this paper as [25]
In the citing paper
“Previous work had identified TLR9, which recognizes unmethylated CpG sequences present in viral or bacterial but not mammalian DNA, as the sensor involved in the induction of type I IFN responses in pDCs 20,22 .”
From AAV vectors trigger DNA damage response-dependent pro-inflammatory signalling in human iPSC-derived CNS models and mouse brain (2025) · cites this paper as [20]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Jayandharan, G. R., Aslanidi, G., Martino, A. T., Jahn, S. C., Perrin, G. Q., Herzog, R. W., & Srivastava, A. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1012753108 · Cited by 72
Self-citationRetractedToll-like receptors and their crosstalk with other innate receptors in infection and immunity
Kawai, T., & Akira, S. (2011) · Immunity · doi:10.1016/j.immuni.2011.05.006 · Cited by 3,658
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163
Jung, S., Unutmaz, D., Wong, P., Sano, G., Santos, K. D. L., Sparwasser, T., Wu, S., Vuthoori, S., Ko, K., Zavala, F., et al. (2002) · Immunity · doi:10.1016/s1074-7613(02)00365-5 · Cited by 1,953
Adenovirus-Associated Virus Vector–Mediated Gene Transfer in Hemophilia B
Nathwani, A. C., Tuddenham, E. G. D., Rangarajan, S., Rosales, C., McIntosh, J., Linch, D. C., Chowdary, P., Riddell, A., Pie, A. J., Harrington, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1108046 · Cited by 1,864
Self-citationLong-Term Safety and Efficacy of Factor IX Gene Therapy in Hemophilia B
Nathwani, A. C., Reiss, U. M., Tuddenham, E. G. D., Rosales, C., Chowdary, P., McIntosh, J., Della Peruta, M., Lheriteau, E., Patel, N., Raj, D., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407309 · Cited by 1,273
Self-citationTherapeutic in vivo gene transfer for genetic disease using AAV: Progress and challenges
Mingozzi, F., & High, K. A. (2011) · Nature Reviews Genetics · doi:10.1038/nrg2988 · Cited by 893
Zhong, L., Li, B., Mah, C. S., Govindasamy, L., Agbandje-McKenna, M., Cooper, M., Herzog, R. W., Zolotukhin, I., Warrington, K. H., Weigel-Van Aken, K. A., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0802866105 · Cited by 558
Self-citationBennett, J., Wellman, J., Marshall, K. A., McCague, S., Ashtari, M., DiStefano-Pappas, J., Elci, O. U., Chung, D. C., Sun, J., Wright, J. F., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30371-3 · Cited by 461
Gaudet, D., Méthot, J., Déry, S., Brisson, D., Essiembre, C., Tremblay, G., Tremblay, K., de Wal, J., Twisk, J., van den Bulk, N., et al. (2013) · Gene Therapy · doi:10.1038/gt.2012.43 · Cited by 404
Cited by
Sorted by citations
Items 101–132 of 132
Pathogenetic value of cell infiltrate in immunoinflammatory rheumatic diseases
Зиявдинович, С. М. (2021) · Medical Immunology (Russia) · doi:10.15789/1563-0625-pvo-2386 · Cited by 4
Assessment of humoral, innate, and T-cell immune responses to adeno-associated virus vectors
Calcedo, R., Chichester, J. A., & Wilson, J. M. (2018) · Human Gene Therapy Methods · doi:10.1089/hum.2018.038 · Cited by 4
Viral vectors in neurodegenerative diseases: immune responses and therapeutic applications
Wang, Y., Mu, S., & Liu, F. (2025) · Frontiers in Neurology · doi:10.3389/fneur.2025.1603125 · Cited by 3
Immunogenicity of Gene and Cell Therapies
Hofman, K., Jangied, P., & Balu‐Iyer, S. V. (2026) · BioDrugs · doi:10.1007/s40259-025-00756-8 · Cited by 3
Current Status of Clinical Gene Therapy for Hemophilia and Globin Disorders
Winkler, R., Herath, I., Kaczmarek, R., Xiao, W., Herzog, R. W., & Severeid, P. (2026) · Journal of Blood Medicine · doi:10.2147/jbm.s576017 · Cited by 3
Self-citationHuang, X., Wang, X., Feng, L., Zhou, R., Chen, W., Jiang, X., Lv, F., Xu, W., Xu, X., Xie, X., et al. (2025) · Life Sciences · doi:10.1016/j.lfs.2025.123742 · Cited by 3
Buranapraditkun, S., Mitchell, J. L., Takata, H., Kroon, E. D. M. B., Pinyakorn, S., Tulmethakaan, N., Manasnayakorn, S., Chottanapund, S., Thantiworasit, P., Prueksakaew, P., et al. (2025) · Journal of Virus Eradication · doi:10.1016/j.jve.2025.100598 · Cited by 2
Gene Therapy for Heart Failure: Impact on Mitochondrial Dysfunction
Blagonravov, M. L., Sklifasovskaya, A. P., Karpov, R. M., Ovechkina, V. S., Andrianova, S. K., Syatkin, S. P., Belousov, V. V., & Mozhaev, A. A. (2026) · Biomedicines · doi:10.3390/biomedicines14020344 · Cited by 2
Holtkamp, S., Lagoda, F. R., Lister, A., Harish, P., Kleymann, U., Pesch, T., Soon, C. F., Pirmohamed, M., Naisbitt, D. J., & Trautwein, M. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1450524 · Cited by 2
Santoscoy, M. C., Espinoza, P., Hanlon, K. S., Yang, L., Nieland, L., Ng, C., Badr, C. E., Hickman, S. E., de la Cruz, D., Griciuc, A., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.09.25.614546 · Cited by 2
Immunology of cell and gene therapy approaches for neurologic diseases
Widner, H. (2024) · Handbook of clinical neurology · doi:10.1016/b978-0-323-90120-8.00018-6 · Cited by 1
Strategies for Evading Cellular Immunity Against Recombinant AAV Vectors in Gene Therapy
Wang, Z., Wu, X., Fu, D.-Y., Li, X., Liu, D., Liu, S., Zhao, Q., & Wang, H. (2026) · Current Medical Science · doi:10.1007/s11596-026-00178-9 · Cited by 2
Xicluna, R., Yamada, K., Gonzalez-Visiedo, M., Greenwood, C. M., Zaugg, D., Waiz, D., Steiner, G., Hahn, K., Schwandt, T., Otteneder, M. B., et al. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.04.014 · Cited by 1
Self-citationMurúa-López, C. D. C., González-Orozco, M., & López-Moreno, H. S. (2019) · Biomédica · doi:10.7705/biomedica.v39i3.4349 · Cited by 1
Host Versus Virus: The Genetics in HCV Infection Leading to Treatment
Maqsood, Q., Hussain, M., & Sumrin, A. (2023) · IntechOpen eBooks · doi:10.5772/intechopen.1001050 · Cited by 1
Mingozzi, F., & Junge, N. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-63671-1.00033-1
Intrathecal Delivery of Viral Vector-Mediated Gene Therapy
Keifer, O. P. (2023) · Springer eBooks · doi:10.1007/978-3-031-39558-1_16
Rewiring Dendritic Cell Immunity: The β-Catenin–TIM-3 Axis as a Target to Improve DC Cancer Vaccines
Fu, C., Ma, T., Zhou, L., Mi, Q., & Jiang, A. (2026) · Cancers · doi:10.3390/cancers18020201
Taming immune responses to AAV gene therapy by programmed in vivo Treg expansion
Gwalani, L. A., Park, M., Ysasi, A. B., Motwani, M., Jackson, R., Bu, J., Luo, Z., Bladon, J. H., Pfister, E. L., Mueller, C., et al. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.02.019
Etude de la réponse immunitaire virale préexistante anti-AAV chez l'homme
Xicluna, R. (2019) · theses.fr (ABES) · doi:10.70675/d2f47d7cz4f46z448cz85afz657c9516c86f
Verdera, H. C. (2019) · theses.fr (ABES) · doi:10.70675/3d2d8524z211ez4408zbdfbz56c065f452a1
Journou, M. (2021) · theses.fr (ABES) · doi:10.70675/9a618ac2za0a4z4e90zbdb3ze14482ffa655
Creisméas, A. (2022) · theses.fr (ABES) · doi:10.70675/7e452f5az22a1z433az83a8z1fe23089846a
Preclinical gene therapy using recombinant AAV vectors in mouse models of two human diseases
Günes, Y. Ö. (2022) · theses.fr (ABES) · doi:10.70675/52c9a808z1652z42c4zae82zc812b95f1723
Etude des réponses T CD8+ après transfert de gène par rAAV ciblant le muscle
Jeanpierre, L. (2024) · theses.fr (ABES) · doi:10.70675/430aceacz50d2z426bz907dz876c55d1e935
Insect-Cell-Produced AAV2 Vectors Activate Myeloid Innate Immune Response Featuring NETosis.
Liu, X., Zhou, Y.-F., Tang, Z., Li, W.-J., Wei, S.-S., & Han, K. (2026) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5c01772
Hu, B., Gutty, V. S. R., Herzog, R. W., & Duan, D. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1930231
Self-citationClinical immunogenicity in rAAV gene therapy: Insights and implications
Gulve, N., Bego, M. G., Gandhi, H., Khan, Z., Tong, O., Katebifar, S., & Rajadhyaksha, M. (2026) · Molecular Therapy Advances · doi:10.1016/j.omta.2026.201848
Zhang, X., Chang, A., Liu, Y., & Yu, H. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1935135
Nano Delivery Systems for In Vivo CRISPR/Cas-Based Gene Therapy: From Vectors to Clinical Outcomes
Chen, R., Zhou, H., Wu, Q., & Gong, C. (2026) · ACS Nano · doi:10.1021/acsnano.6c12154
Metadata
- Authors
- Rogers, G. L., Shirley, J. L., Zolotukhin, I., Kumar, S. R. P., Sherman, A., Perrin, G. Q., Hoffman, B. E., Srivastava, A., Basner-Tschakarjan, E., Wallet, M. A., Terhorst, C., Biswas, M., & Herzog, R. W.
- Affiliations
- University of Florida Health (US)
- Center of Molecular and Cellular Therapeutics, The Children’s Hospital of Philadelphia, Philadelphia, PA;
- University of Florida (US)
- Beth Israel Deaconess Medical Center (US)
- ORCID
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2017-06-15
- Volume
- 129
- Issue
- 24
- Pages
- 3184-3195
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- PMC
- PMC5472899
- OpenAlex
- W2610861971
- Semantic Scholar
- e6cfb89e4d66a95c980f78792a7ed364f7e69294
- Cited by
- 131
- References
- 60
- Citations by year
- 2026: 14 · 2025: 13 · 2024: 16 · 2023: 17 · 2022: 15 · 2021: 19 · 2020: 7 · 2019: 15 · 2018: 11 · 2017: 4
- FWCI
- 4.57
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Blood (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- National Heart, Lung, and Blood Institute (HL-097088, HL131093, R01HL097088, R01HL131093)
- National Institute of Allergy and Infectious Diseases (R01AI051390, R01 AI51390, T32AI007110)
- National Institute of Diabetes and Digestive and Kidney Diseases (UC4DK104194)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- plasmacytoid dendritic cells, myeloid dendritic cells, cross-presentation, AAV capsid, CD8+ T cells, viral DNA sensing, innate immunity
- MeSH terms
- Dependovirus, Animals, Dendritic Cells, Lymphocyte Activation, Plasma Cells, Genetic Therapy, Mice, Knockout, CD8-Positive T-Lymphocytes, Capsid Proteins, Toll-Like Receptor 9, Mice, Myeloid Differentiation Factor 88
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
